TY  - GEN
AU  - Jonasch,Eric
AU  - Wood,Christopher G
AU  - Matin,Surena F
AU  - Tu,Shi-Ming
AU  - Pagliaro,Lance C
AU  - Corn,Paul G
AU  - Aparicio,Ana
AU  - Tamboli,Pheroze
AU  - Millikan,Randall E
AU  - Wang,Xuemei
AU  - Araujo,John C
AU  - Arap,Wadih
AU  - Tannir,Nizar
TI  - Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
SN  - 1527-7755
PY  - 2009///0915
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Angiogenesis Inhibitors
KW  - administration & dosage
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bevacizumab
KW  - Carcinoma, Renal Cell
KW  - drug therapy
KW  - Chemotherapy, Adjuvant
KW  - Disease-Free Survival
KW  - Erlotinib Hydrochloride
KW  - Feasibility Studies
KW  - Female
KW  - Humans
KW  - Kaplan-Meier Estimate
KW  - Kidney Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Neoadjuvant Therapy
KW  - Nephrectomy
KW  - Proportional Hazards Models
KW  - Prospective Studies
KW  - Quinazolines
KW  - Risk Assessment
KW  - Time Factors
KW  - Treatment Outcome
KW  - Wound Healing
KW  - drug effects
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1200/JCO.2008.21.3660
ER  -